-
Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux’s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were…
-
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
•
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept (POC) study for minzasolmin, an alpha-synuclein misfolding inhibitor co-developed with Swiss pharmaceutical giant Novartis (NYSE: NVS). The study was designed to assess the efficacy of minzasolmin in treating early Parkinson’s disease, but it failed to…
-
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
•
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products and local partnerships in the Chinese market by signing an agreement with Zhejiang based BioRay Pharmaceutical Co., Ltd. for the commercial promotion of its Bimzelx (bimekizumab) in China. The financial details of the deal have…
-
CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million
•
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company based in Abu Dhabi, have jointly announced the strategic acquisition of Belgium-based biopharma UCB’s (FRA: UNC) mature neurology and allergy business in China. The deal is valued at USD 680 million and includes UCB’s well-known…
-
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
•
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration (FDA) has granted another indication approval for its drug Bimzelx (bimekizumab), an interleukin 17A (IL-17A) and IL-17F targeted antibody. The FDA has approved Bimzelx for the treatment of adults with moderate to severe hidradenitis suppurativa…
-
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
•
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a Phase III study of their co-developed drug candidate, dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L agent, when combined with the standard-of-care (SOC) in patients with moderate-to-severe systemic lupus erythematosus (SLE). The findings, which indicate a…
-
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn from the US industry trade group Biotechnology Innovation Organization (BIO). This decision follows a similar trend set by Pfizer (NSE: PFIZER), UCB (EBR: UCB), WuXi AppTec (HKG: 2359, SHA: 603259), Takeda (TYO: 4502), and other…
-
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
•
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA) filing with the US FDA for its FcRn blocker nipocalimab. The drug’s initial indication is anticipated to be for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for certain antibodies. This…
-
Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs
•
China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing approvals in China for two advanced treatments targeting neurodegenerative and autoimmune conditions, according to the Center for Drug Evaluation (CDE) website. Tonghua Golden-Horse’s octohydroaminoacridine succinate, designed to treat mild to moderate Alzheimer’s disease (AD), and…
-
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
•
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced the signing of a definitive agreement to divest its established neurology and allergy business in China. The transaction involves the sale to two prominent investment firms, the Singapore-based CBC Group and the Abu Dhabi-based Mubadala,…
-
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
•
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a Phase III clinical study for its anti-IL-17A monoclonal antibody (mAb) in the treatment of moderate to severe plaque psoriasis. The study, which was approved in China in February 2020, marks a significant step forward in…
-
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
•
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution after an overseas inspection uncovered inconsistent expiration date labeling. The decision affects batches manufactured and packaged abroad, with UCB initiating a voluntary recall and cooperating to resolve the issue. Company ResponseUCB announced the recall of…
-
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced that its randomized, double-blind, placebo-controlled, multi-dose escalation and dose exploration Phase II clinical study for the anti-IL-17A monoclonal antibody (mAb) SSGJ-608 in moderate to severe plaque psoriasis has reached its primary endpoint. Study DetailsThe study,…
